FBIO
Fortress Biotech, Inc.Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsBEARISH
Q2 2026: 2 added (0 new), 6 trimmed or exited.
- EstimatesFALLING
Current-quarter EPS estimate −$0.150 → −$0.270 over 90 days. 0 up, 1 down in 30 days.
- TrendDOWNTREND
21% below its 50-day average. New closing low $1.87 on Oct 26.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| CITADEL ADVISORS LLC | TRIM | $235.8K |
| NORTHERN TRUST CORP | TRIM | $194.7K |
| UBS Group AG | DOUBLED | $160.2K |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | NEAR_EXIT | $143.8K |
| JANE STREET GROUP, LLC | TRIM | $77.8K |
| SIMPLEX TRADING, LLC | NEAR_EXIT | $44.4K |
| OSAIC HOLDINGS, INC. | ADD | $27.7K |
| WELLS FARGO & COMPANY/MN | TRIM | $15.3K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
last action Feb 2026Price is below the lowest target. Median implies +167%.Targets as of Oct 26, 2026.
| Date | Firm | Rating |
|---|---|---|
| Feb 23, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Aug 21, 2025 | HC Wainwright & Co. MAINTAIN | Buy |
| Mar 11, 2025 | Roth MKM REITERATE | Buy |
| Nov 18, 2024 | HC Wainwright & Co. MAINTAIN | Buy |
| Jul 19, 2024 | HC Wainwright & Co. REITERATE | Buy |
| Jun 20, 2024 | Cantor Fitzgerald REITERATE | Overweight |
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Oct 1, 2026 | Jin David Chief Financial Officer | AWARD | $2.2K |
| Jun 22, 2026 | Jin David Chief Financial Officer | AWARD | 400,000 sh |
| Apr 1, 2026 | Jin David Chief Financial Officer | AWARD | $6.5K |
| Mar 18, 2026 | WEISS MICHAEL S Executive Vice Chairman | AWARD | 475,424 sh |
| Mar 18, 2026 | ROSENWALD LINDSAY A MD PRESIDENT, CEO & CHAIRMAN | AWARD | 475,424 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.27 | -$0.27–-$0.27 | -80.0% | $21.6M |
| Next Q | -$0.25 | -$0.25–-$0.25 | -78.6% | $22.5M |
| Current FY | $2.55 | $2.55–$2.55 | +6.2% | $78.8M |
| Next FY | -$1.00 | -$1.00–-$1.00 | -100.0% | $113.3M |
Short side
FINRA· Oct 15, 2026SecBot reports
3 filings · 1 press release · 1 bullish · 0 bearish · 2 neutral- BULLISH 8-KOct 1, 2026
Fortress Biotech repaid the remaining $15.0 million in outstanding principal under its Oaktree…
With the Oaktree facility fully repaid and terminated, Fortress Biotech has eliminated a significant debt burden. Monitor upcoming quarterly filings for cash runway and any new financing plans, as…
- NEUTRAL PRESS-RELEASEMay 18, 2026
Fortress Biotech announced CEO participation in a fireside chat at A.G.P.'s Virtual Healthcare…
Monitor the conference for any strategic commentary or pipeline updates, but this filing alone provides no actionable trading signal.
- NEUTRAL PRESS-RELEASEMay 4, 2026
Fortress Biotech announced CEO participation in a fireside chat at the H.C. Wainwright Royalty…
This is a non-event for traders. No financial data, guidance, or material developments were disclosed. Monitor upcoming quarterly results for any substantive updates on pipeline or revenue.
- BULLISH PRESS RELEASEMar 30, 2026
Fortress Biotech announced the closing of the $205 million sale of a Rare Pediatric Disease…
The >$100M in expected proceeds provides Fortress with substantial capital to advance its clinical pipeline, pursue acquisitions, or return capital to shareholders. Given the company's current…
All FBIO filing & press-release reports (4)
- 8-K reportOct 1, 2026
- PRESS-RELEASE reportMay 18, 2026
- PRESS-RELEASE reportMay 4, 2026
- PRESS-RELEASE reportMar 30, 2026